COVID 19 being the pandemic disease and not able to be contained by what ever-existing facility, a vaccine is the only hope for the future.
On various platforms, vaccines are under trial either in pre clinical or phase 1 testing (current clinical evaluation status). These are Non replicating virus vector, replicating viral vector, live-attenuated, Inactivated-killed, RNA, DNA, Protein subunit types.
Eg. Adenovirus type 5 vector and LNP encapsulated mRNA...
DRAFT landscape of COVID-19 candidate vaccines – 20 March 2020 Rituja Kaushal
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
the vaccine approaches which will induce cellular immunity will be appropriate against SARS-CoV-2
Currently, therapies and vaccines based on blood plasma from people who have previously become infected with the SARS-CoV-2 Coronavirus and are mildly past Covid-19 disease are being tested in some countries, i.e. they fought the disease with their body's immune system. In the blood plasma collected from people who have recovered, there are usually many antibodies to the SARS-CoV-2 Coronavirus, i.e. the natural mechanisms of defense against this virus produced by the human body, thus preventing serious, severe Covid-19 disease.
Regards,
Dariusz Prokopowicz
Thank you sir. What are the vaccines on human trial?@Sadananda Pandey.
Hello Nirmal Mohakud
Considering many demerits as a backdrop for a decline in the conventional vaccine designing, in silico or computaion based vaccine development approach is also being being sought widely . This approach, that helps in constructing a multi-epitopes based vaccine is advantageous in many ways, which includes:
- Epitopes of the vaccine bind to various MHC Class I and Class II molecules that can in turn be recognized by T cell Receptors from various T cell subsets
- They have the capacity to activate both humoral and cellular immune responses simultaneously
- They can be linked with an adjuvant, hich can elicit the immune response from TLRs
- Overcome complications of in vitro antigen expression as well as the difficulty and confusions of culturing the pathogens, alongwith a significant decline in the costs and duration.
As a result of this, many researchers are being encouraged to design vaccine based on this approach, and you get to see lots of them getting published as well. Had all these work been converted to in vitro work as well, a promising vaccine can be developed out of them.
Hope it helps.
All the vaccine development projects for COVID-19 halt because the shocking news is that the immunity to COVID-19 is short lived.
So no immunity passport, herd immunity, or even protection from COVID-19 reinfection.
Please open the link and ponder:
https://www.medrxiv.org/content/10.1101/2020.06.13.20130252v1.full.pdf
Moderna Inc and Pfizer Inc launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Monday.
Its really good news.